Published in

Nature Research, Nature Reviews Cancer, 3(9), p. 182-194, 2009

DOI: 10.1038/nrc2561

Links

Tools

Export citation

Search in Google Scholar

Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies

Journal article published in 2009 by Jeff S. Isenberg, Gema Martin-Manso, Justin B. Maxhimer, David D. Roberts ORCID
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In addition to long-term regulation of angiogenesis, angiogenic growth factor signalling through nitric oxide (NO) acutely controls blood flow and haemostasis. Inhibition of this pathway may account for the hypertensive and pro-thrombotic side effects of the vascular endothelial growth factor antagonists that are currently used for cancer treatment. The first identified endogenous angiogenesis inhibitor, thrombospondin 1, also controls tissue perfusion, haemostasis and radiosensitivity by antagonizing NO signalling. We examine the role of these and other emerging activities of thrombospondin 1 in cancer. Clarifying how endogenous and therapeutic angiogenesis inhibitors regulate vascular NO signalling could facilitate development of more selective inhibitors.